

A Study on Quality Control Tests for Dosage Forms and their Effect on Physical, Chemical and Biological Specifications: A Review

Darwn H. Kak Bchkol

School of Natural and Applied Science, Department of Chemistry-Firat University, Turkey

Ali Hameed Abdulkareem, Fatima Ahmed Habib

Independent Researcher, Iraq

Abstract: The main criteria for quality of any drug in solid dosage forms (tablets and capsules) and liquid dosage forms (syrup) are its safety, potency, efficacy, stability, patient acceptability and regulatory compliance. At the product design and formulation stage the physical, chemical and biological specifications, to which the product must comply with to fulfill quality requirements, have to determine and the target for quality must be set. In-process quality control (IPQC) tests are strongly related to final products quality because checks performed during production in order to monitor and if necessary to adjust the process to ensure that the product conforms to its specification are the key for good quality pharmaceutical tablets. The purposes of IPQC are to produce a perfect finished product by preventing or eliminating errors at every stage in production. After the manufacturing process is complete, finished product quality control (FPQC) tests for pharmaceutical tablets, capsules and suppositories are performed with respect to specification of the pharmacopoeias in order to check that the quality parameters are within acceptance limits or not. The aim of this study is to provide review of physical and chemical quality control tests for solid dosage forms, liquids (syrups) in-process and finished products quality control tests for pharmaceutical products according to pharmacopoeias. The tests described are essential for ensuring the safety and efficacy of these products.

Keywords: Solid dosage forms, liquid dosage form, Pharmacopoeia, In-process quality control, finished product quality control, Specificatio.

1. INTRODUCTION

Quality is not an accident this is the result of intelligent effort [1]. The quality in the pharmaceutical industry has become a very important and sensitive issue. Since the world has gathered together to unite its practices, guides and the launching of the Food and Drug Administration (FDA) current good manufacturing practices (cGMP) for the 21st century - there has been a growing awareness for the significance of the quality of the pharmaceutical products. In the pharmaceutical industry, it is essential for controlling the errors during the every stage in production process since total quality of the product must be ensured according to compendia of drugs [2]. Manufacturing practices which result in good quality finished products and has adequate considerations for safety of the employees is recognized as GMP. GMP is concerned with both production and quality control (QC) [3]. QC is the part of GMP by which QC personnel analyses the quality of all factors involved in production in order to eliminate errors at every stage in production. The purposes of QC are to produce a perfect finished product by preventing

or eliminating errors at every stage in production. QC is a team work and we have to remember that quality must be built into a drug product during product and process design and it is influenced by the physical plant design, space, ventilation, cleanliness and sanitation during routine production [4].

IPQC tests are performed at regular intervals (generally each 1 hr later) during the manufacturing process [5]. The objectives of IPQC involve monitoring and alteration of the manufacturing process if necessary with a vision to comply with the specifications. The control of the environment or equipment may also be regarded as a part of in process control (IPC). They should not carry any risk for the quality of product. In process testing enables easier identification of problems. It sometime identifies a defective product batch that can be corrected by rework, whereas once that batch has been completed, this may not be possible. Failure to meet IPC specification indicates either those procedures were not followed or some factors were out of control [6]. Standard operating procedures (SOPs) should be established in the pharmaceutical industry and followed that describe the IPQCs and tests [7].

FPQCs are tests that are performed when the manufacturing process is completed in order to check qualitative and quantitative characteristics along with test procedures and their acceptance limits by which the finished product must comply throughout its valid shelf-life [8]. In order to determine the specifications of the finished product, the quality characteristics related to manufacturing process should be taken into account. An appropriate specification for each aspect of quality studied during the phase of development and during the validation of the manufacturing process should be determined. At least those aspects considered to be critical should be the object of specifications routinely verified. The specification limits of the finished product at the time of batch release are set by the marketing authorization applicant such that the specifications proposed at the end of shelf-life are guaranteed and are established on the basis of a critical detailed review of the data gathered from the batches analyzed [9].

Pharmacopoeias are called drugs standard [10]. There are various types of pharmacopoeia represented in Figure 1.1 such as Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), United States Pharmacopoeia (USP), European Pharmacopoeia (PhEur), International Pharmacopoeia (PhInt) and Japanese Pharmacopoeia (JP) in different parts of the world and they have laid down the specified limits within which the value should fall in order to be compliant as per the standards. The objective of this study is to show the quality parameters for pharmaceutical tablets and capsules according to pharmacopoeias that are part of in-process and finished products quality control tests.



Figure 1.1. List of pharmacopoeia

Dosage form is defined as a physical form of a drug such as; a solid, liquid or gas by which it is delivered in it's a proper form to particular sites of action within the body as shown in figure 1.2. The pharmaceutical analysis of finished solid oral dosage forms is presented here from the aspect of what makes the delivery form unique and successful, i.e., the physical properties and the state of the drug substance in the matrix. During product development, many analytical techniques can be brought to bear that provide a characterization of the product and guide the pathway to the

optimum formula. In many cases, analytical techniques can be used to assess the effects of processing parameters and provide a means to predict the performance and stability of the final product. Pharmaceutical solid dosage forms for oral use are the most common pharmaceutical formulation types worldwide. They are complex multicomponent system that may be available in many diverse structures such as powders, granule, compressed tablet, chewable tablet and capsules [11,12]. Dosage form = Active Pharmaceutical Ingredient (API) + Excipients/additives.



Figure 1.2. Dosage form composition.

Solid oral dosage forms were the first dosage forms to be considered for worldwide regulation by the International Conference on Harmonization (ICH) as shown figure 1.3. The ICH is a collaborative effort by both industry and regulatory bodies of the United States, the European Union, and Japan [13,14]. Preliminary physicochemical assessment of drug products has a paramount importance in ensuring the quality of drug products. Generic drug products must satisfy the same standards of quality, efficacy and safety as those applicable to the innovator products. In vitro dissolution testing can be a valuable predictor of the in vivo bioavailability and bioequivalence of oral solid dosage forms [15]. When it is incorporated into polymers that are used to modify its physical state or control its release in the gastrointestinal tract. These formulations often present considerable challenges to the pharmaceutical chemist. Solid oral dosage forms are designed to deliver the drug through physiological mechanisms that preside throughout the gastrointestinal tract [16].




Figure 1.3. Classification of solid dosage forms

The problem of quality assessment of pharmaceutical solid dosage form is important all over the world [17]. Ensuring the quality of medicine is becoming more important and challenging. This generates the need for more fast and smart technique to fulfil the requirement. Pharmaceutical analysis deals with analysis of drugs, pharmaceutical substances and raw material. It is devoted to stability testing, comparing related substances, determination of impurities. There are various techniques are available for analysis of pharmaceutical solid dosage forms [18].

Liquid dosage forms are pourable pharmaceutical formulations comprising of API and excipients either dissolved or dispersed in a suitable solvent as represented in Figure 1.4. These are intended to offer a fast therapeutic response in people with trouble swallowing solid dosage forms. Liquid dosage forms are available as ready-to-use liquids or dry powders for reconstitution. These can be administered by oral (syrups, suspensions, etc.) and/or parenteral (injectable, ophthalmic, nasal, otic and topical) routes. Oral liquids are generally nonsterile, while the parenteral liquid dosage forms are offered as sterile and non-sterile formulations [19].



Figure 1.4. Sterile and non-sterile liquid dosage forms.

The objective of this study is to show the quality parameters for pharmaceutical such as physical and chemical quality control tests for solid dosage forms, liquids (syrups) in-process and finished products quality control tests for pharmaceutical products according to pharmacopoeias. The tests described are essential for ensuring the safety and efficacy of these products.

2. RESULTS and DISCUSSIONS

2.1 Universal And IPQC Tests For Pharmaceutical Tablets

The tablet dosage form accounts for approximately 50% of all dosage forms on the market. There are four tests that are generally applicable to pharmaceutical tablets and other drug products:

2.1.1 Description

This test is often called appearance on a specification and is a qualitative description of the pharmaceutical tablet. For example, the description of a tablet on a specification may read: white, round, biconvex, film-coated tablet, imprinted with “Rx” on one side [20].

2.1.2 Identification

The purpose of an identification or identity test is to verify the identity of the active pharmaceutical ingredient (API) in the pharmaceutical tablet. This test should be able to discriminate between compounds of closely related structure that are likely to be present [20].

2.1.3 Impurities

This test determines the presence of any component that is not the API or an excipient of pharmaceutical tablet. The most common type of impurities that are measured is related substances, which are process impurities from the new drug substance synthesis, degradation products of the API, or both [20].

2.1.4 Assay

This test measures the total amount of active ingredient in a sample of tablets or capsules.

This is important to ensure that the product contains the correct amount of medication [21].

2.2 IPQC and FPQC Tests

Physical parameters of pharmaceutical tablets that are controlled by IPQC tests are temperature, pressure, moisture content, time, weight, particle size, hardness, loss on drying, disintegration time, color, compactness, integrity etc. FPQC test for pharmaceutical tablets are assay, uniformity of content uniformity of mass, weight variation, friability test, content of active

ingredients, hardness test, disintegration test, dissolution test etc. IPQC and FPQC test for pharmaceutical tablets according to pharmacopoeias are listed below:

2.2.1 Size and Shape

The size and shape of the tablet can be dimensionally described, monitored, and controlled. A compressed tablet's shape and dimensions are determined by the tooling during the compression process. The thickness of a tablet is the only dimensional variable related to the process. At a constant compressive load, tablet thickness varies with changes in die fill, with particle size distribution and packing of the particle mix being compressed, and with tablet weight, while with a constant die fill, thickness varies with variations in compressive load[22].

2.2.2 Color

Many pharmaceutical tablets use color as a vital means of rapid identification and consumer acceptance. The color of a product must be uniform within a single tablet (non uniformity is generally referred to as "mottling"), from tablet to tablet, and from lot to lot. Non uniformity of coloring not only lacks esthetic appeal but could be associated by the consumer with non uniformity of content and general poor quality of the product.⁸ The eye cannot discriminate small differences in color nor can it precisely define color. The eye has limited memory storage capability for color, and the storage of visually acquired data is difficult, which results in people perceiving the same color differently and a single person describing the same color differently at different times. In addition, visual color comparisons require that a sample be compared against some color standard. Color standards themselves are subject to change with time, thus forcing their frequent redefinition, which can lead to a gradual and significant change in acceptable color. Efforts to quantitate color evaluations have used reflectance spectrophotometry, tristimulus colorimetric measurements, and the use of a micro- reflectance photometer to measure the color uniformity and gloss on a tablet surface[23,24].

2.2.3 Odor

The presence of an odor in a batch of tablets could indicate a stability problem, such as the characteristic odor of acetic acid in degrading aspirin tablets[^] however, the presence of an odor could be characteristic of the drug, (vitamins have a characteristic odor), added ingredients (flavoring agents have pleasant odors), or the dosage form (film-coated tablets usually have a characteristic odor) [25].

2.2.4 Taste

Taste is important in consumer acceptance of chewable tablets. Many companies utilize taste panels to judge the preference of different flavors and flavor levels in the development of a product. Owing to the subjectiveness of "taste" preference, however, the control of taste in the production of chewable tablets is often simply the presence or absence of a specified taste[26].

2.2.5 Appearance

Tablets defects and surface roughness (specially for coated types) are also investigated. A tablet's level of flaws such as chips, cracks, contamination from foreign solid substances (e.g., hair, drops of oil, and "dirt"), surface texture ("smooth" versus "rough"), and appearance ("shiny" versus "dull") may have a zero-defect 10 specification, but the visual inspection techniques used for detecting or evaluating these characteristics are subjective in nature. Electronic devices that are currently being developed hold promise for making inspection a more quantitative and reproducible operation[27].



Figure 2.1. organoleptic properties

2.2.6 Unique Identification Markings

Pharmaceutical companies often use some type of unique markings on tablets in addition to color, for rapid identification of their product these markings utilize some form of embossing, engraving or printing of the company name or symbol or a product code [28].

2.2.7 Moisture Content of Granules

Granules should possess sufficient strength to withstand normal handling and mixing processes without breaking down and producing large amounts of fine powder. On the other hand, some size reduction during compaction into tablets is desirable to expose the areas of clean surface necessary for optimum bonding to take place so moisture content is the very important factor for producing good pharmaceutical product [29].

2.2.8 Weight Variation Test

According to the USP weight variation test is run by weighting 20 tablets individually calculating the average weights and comparing the individual tablet weights to the average. The value of weight variation test is expressed in percentage. The following formula is used:

Weight Variation = $(Iw - Aw)/Aw \times 100$ Where,

Iw = Individual weight of tablet; Aw = Average weight of tablet.

As per USP the tablet complies with the test if not more than 2 of the individual masses deviate from the average mass by more than the percentage deviation as shown in Table 1.1. and none deviates by more than twice that percentage [30].

Table 1.1. USP limits for weight variation test for uncoated tablets

Average Weight (mg)	% deviation
130 mg or less	10%
More than 130 mg and less than 324 mg	7.5%
More than 324 mg	5%

2.2.9 Content uniformity test

It is performed to ensure the proper mixing of the tablet contents by determining individually the content of 10 tablets taken randomly and determine average content. According to USP, content uniformity test is done for uncoated & film-coated tablets containing less than 25% of the total weight and for all sugar coated tablets. Not more than one tablet falls outside the limit 85-115% of the average content and none outside the limit 75-125% of the average content [31].

2.2.10 Thickness

The thickness of a tablet is the only dimensional variable related to the process. Thickness of individual tablets may be measured by a micrometer as shown in Figure 2.2. Other techniques involve placing 5 or 10 tablets in a holding tray, where their total thickness may be measured by

a sliding caliper scale. Tablet thickness should be controlled within a $\pm 5\%$ variation of a standard. Thickness must be controlled to facilitate packaging. It is expressed in mm [32].



Figure 2.2. Types of micrometer.

2.2.11 Hardness Test

For this test one of the earliest testers was Ketan tablet hardness tester, which is a type of the Monsanto hardness tester to evaluate tablet hardness tester as given in Figure 2.3. The tester consists of a barrel containing a compressible spring held between two plungers. The lower plunger is placed in contact with the tablet and zero reading is taken. The upper plunger is then forced against a spring by turning a threaded bolt until the tablet fractures. As the spring is compressed, a pointer rides along a gauge in the barrel to indicate the force. The force of fracture is recorded in kilogram [33]. Ten tablets are crushed and measure their hardness and the allowable range is between 4 - 6 kg (40 - 60 N) unless otherwise specified.



Figure 2.3. Hardness tester

2.2.12 Friability Test

Friability of a tablet can determine in laboratory by Roche friabilator as represented in Figure 2.4. For this test twenty tablets are weighed and placed in the friabilator and then operated at 25 rpm for 4 minutes. The tablets are then dedusted and weighed. The difference in the two weights is used to calculate friability and the value of friability is expressed in percentage. It is determined by the following formula: $\text{Friability} = (Iw - Fw)/Iw \times 100\%$

Where, Iw = Total Initial weight of tablets; Fw = Total final weight of tablets.

As stated by USP if conventional compressed tablets that loss less than 0.5 % to 1 % (after 100 revolutions) of their weight are generally considered acceptable [34].



Figure 2.4. Friability tester

2.2.13 Disintegration Test

The USP disintegration apparatus consist of 6 glass tubes that are 3 inches long, open at the top, and held against a 10-mesh screen at the bottom end of the basket rack assembly. To test for disintegration time, one tablet is placed in each tube and the basket rack is positioned in specified medium at 37 ± 2 °C such that tablet remains 2.5 cm below the surface of the liquid on their upward movement and descend not closer than 2.5 cm from the bottom of the beaker. A standard motor driven device is used to move the basket assembly containing the tablets up and down through distance of 5 to 6 cm at a frequency of 28 to 32 cycles per minute. Perforated plastic discs may also be used in the test. These are placed on the top of tablets and impart an abrasive action to the tablets. The discs may or may not be meaningful or impart more sensitivity to the test, but they are useful for tablets that float [34,35]. Operate the apparatus for the specified time(15 minutes for uncoated tablet unless otherwise justified and authorized). The tablet complies with the test, if the tablets disintegrate, and all particles pass through the 10- mesh screen in the time specified. If any residue remains, it must have a soft mass with no palpably firm core.



Figure 2.5. Disintegration tester

The tablet complies with the test according to USP, if all of the tablets have disintegrated completely [36] .If 1 or 2 tablets fail to disintegrate completely, repeat the test on 12 additional tablets. The requirement is met if not less than 16 of the total of 18 tablets tested are disintegrated. The BP limits for disintegration times of tablets are given in Table 1.2.

Tablet 1.2. BP limits for disintegration times of tablets

Categories of Tablets	Disintegration Time (min)
Uncoated tablets	15
Coated tablets	60
Effervescent tablets	5
Soluble tablets	3
Dispersible tablets	3
Orodispersible tablets	3
Gastro-resistant tablets	60
Oral lyophilisates	3

2.2.14 Dissolution Test

The BP or USP dissolution apparatus (Basket apparatus) consist of a cylindrical vessel with a hemispherical bottom, which may be covered, made of glass or other inert, transparent material;

a motor; a metallic drive shaft; and a cylindrical basket. The vessel is partially immersed in a suitable water bath of any convenient size or heated by a suitable device such as a heating jacket. The water bath or heating device permits holding the temperature inside the vessel at $37 \pm 0.5^\circ\text{C}$ during the test and keeping the bath fluid in constant, smooth motion as given in Figure [2.6]



Figure 2.6. Drug Dissolution tester

For this test according to BP and PhEur place the stated volume of the dissolution medium ($\pm 1\%$) in the vessel of the specified apparatus. Assemble the apparatus, equilibrate the dissolution medium to $37 \pm 0.5^\circ\text{C}$. Place 1 tablet in the apparatus, taking care to exclude air bubbles from the surface of the tablet. Operate the apparatus at the specified rate. Within the time interval specified, or at each of the times stated, withdraw a specimen from a zone midway between the surface of the dissolution medium and the top of the rotating basket or blade, not less than 1 cm from the vessel wall. Where multiple sampling times are specified, replace the aliquots withdrawn for analysis with equal volumes of fresh dissolution medium at 37°C or, where it can be shown that replacement of the medium is not necessary, correct for the volume change in the calculation. Keep the vessel covered for the duration of the test and verify the temperature of the medium at suitable times. Perform the analysis using a suitable assay method as directed in the individual monograph. Repeat the test with additional tablets [37,38,39]. Unless otherwise specified in the individual monograph, according to BP, USP, PhEur, JP and PhInt the requirements are met if the quantities of active ingredient dissolved from the tablets tested conform to the following acceptance criteria Table 1.3 .

Table 1. 3. BP, USP, PhEur, JP and PhInt acceptance criteria for dissolution test of tablet

Stage	No. of tablet tested	Acceptance criteria
S1	6	Each unit is not less than $Q + 5\%$.
S2	6	Average of 12 units ($S1 + S2$) is equal to or greater than Q , and no unit is less than $Q - 15\%$.
S3	12	Average of 24 units ($S1 + S2 + S3$) is equal to or greater than Q , not more than 2 units are less than $Q - 15\%$, and no unit is less than $Q - 25\%$.

2.3 Universal Tests For Pharmaceutical Capsules

Physical parameters of pharmaceutical capsules that are controlled by IPQC tests are temperature, pressure, relative humidity, particle size, color, fill weight, shell weight, soft gel ribbon thickness, soft gel seal thickness, soft gel shell moisture level, soft gel hardness, disintegration time etc. FPQC test for pharmaceutical capsules are assay, fill weight, uniformity of content, uniformity of mass, mass variation, microbiological test, disintegration test, dissolution test, stability test etc [40]. The capsule dosage form accounts for approximately 10% of all dosage forms on the market. There are four tests that are generally applicable to pharmaceutical capsules and other drug products:

2.3.1 Description

This test is often called appearance on a specification and is a qualitative description of the pharmaceutical capsules. For example, the description of a capsule on a specification may read: white cap, red body, imprinted with “Rx” on cap.

2.3.2 Identification

The purpose of an identification or identity test is to verify the identity of the API in the pharmaceutical capsule. This test should be able to discriminate between compounds of closely related structure that are likely to be present.

2.3.3 Assay

This test determines the strength or content of the API in the pharmaceutical capsule and is sometimes called a content test [40].

2.3.4 Impurities

This test determines the presence of any component that is not the API or an excipient of pharmaceutical capsule. The most common type of impurities that are measured is related substances, which are process impurities from the new drug substance synthesis, degradation products of the API, or both[41].

2.4 IPQC and FPQC Tests

2.4.1 Appearance

Capsules produced on a small or a large scale should be uniform in appearance. Visual or electronic inspection should be undertaken to detect any flaws in the integrity and appearance of the capsule. Evidence of physical instability is demonstrated by gross changes in appearance, including hardening or softening, cracking, swelling, mottling, printing mistake or discoloration of the shell. Defective capsules should be rejected [42].

2.4.2 Size and Shape

Hard capsules are made in a range of sizes, the standard industrial ones in use today for human medicines range from size 000 (the largest, 1.40 ml) to 5 (the smallest, 0.13 ml) are commercially available. Soft gel capsules are available in variety of shapes such as spherical (0.05–5 ml), ovoid (0.05–7 ml), cylindrical (0.15–25 ml), tubes (0.5–0 ml), pear (0.3–5 ml) etc [43].

2.4.3 Unique Identification Markings

Capsule surfaces may bear symbols or other unique identification markings for better identification.

2.4.4 Assay

In a capsule an active ingredient is present which is called API. So to prepare the capsule assay has to be done by using suitable analytical method to produce good finished product.

2.4.5 Content of Active Ingredients

For this test a sample of the contents is assayed as described in individual monographs and calculates the amount of active ingredient in each capsule. According to IP the range for the content of active ingredient stated in the monograph is based on the requirement that 20 capsules, or such other number as may be indicated in the monograph, are used in the assay. In the circumstances where 20 capsules cannot be obtained, a smaller number, which must not be less than 5, may be used, but to allow for sampling errors the tolerances are widened in accordance with Table 1.4. The requirements of the Table 1 apply when the stated limits are between 90 and 110 percent. For limits other than 90 to 110 percent, proportionately smaller or larger allowances should be made [44].

Table 1.4: IP limits for content of active ingredients

Weight of active ingredients in each capsule (g)	Subtract from lower limit for samples of			Add to the upper limit for samples of		
	15	10	5	15	10	5
0.12 or less	0.2	0.7	1.5	0.3	0.8	1.8
More than 0.12 But less	0.2	0.5	1.2	0.3	0.6	1.5
0.3 or more	0.1	0.2	0.8	0.2	0.4	1.0

2.4.6 Mass Variation Test

For hard capsules according to BP accurately weigh 10 capsules individually, taking care to preserve the identity of each capsule. Remove the contents of each capsule by suitable means. Accurately weigh the emptied shells individually, and calculate for each capsule the net mass of its contents by subtracting the mass of the shell from the respective gross mass. Calculate the active substance content in each capsule from the mass of product removed from the individual capsules and the result of the assay. Calculate the AV using the following formula:

$$X_i = W_i \times A/W$$

Where,

x_1, x_2, \dots, x_n = Individual estimated contents of the dosage units tested. w_1, w_2, \dots, w_n = Individual masses of the dosage units tested.

Content of active substance (percentage of label claim) obtained using an appropriate analytical method (assay). W = Mean of individual weights (w_1, w_2, \dots, w_n) [15]. For soft capsules consistent with BP accurately weigh 10 intact capsules individually to obtain their gross masses, taking care to preserve the identity of each capsule. Then cut open the capsules by means of a suitable clean, dry cutting instrument such as scissors or a sharp open blade, and remove the contents by washing with a suitable solvent. Allow the occluded solvent to evaporate from the shells at room temperature over a period of about 30 min, taking precautions to avoid uptake or loss of moisture. Weigh the individual shells, and calculate the net contents. Calculate the active substance content in each capsule from the mass of product removed from the individual capsules and the result of the assay. Calculate the AV using the following formula given above [15] According to BP and USP, the requirement is met if the acceptance value of 10 capsules is less than or equal to 15 percent. If acceptance value is greater than 15 percent, test the next 20 capsule and calculate the acceptance value. The requirements are met if the final acceptance value of the 30 capsule is less than or equal to 15 percent and no individual content of the capsule is less than $(1 - 25 \times 0.01) M$ or more than $(1 + 25 \times 0.01) M$ in calculation of acceptance value under mass variation or content uniformity [45,46].

2.4.7 Disintegration Test

The USP disintegration apparatus consist of 6 glass tubes that are 3 inches long, open at the top, and held against a 10-mesh screen at the bottom end of the basket rack assembly. To test for disintegration time, one capsule is placed in each tube and the basket rack is positioned in specified medium at $37 \pm 2^\circ\text{C}$ such that capsule remains 2.5 cm below the surface of the liquid on their upward movement and descend not closer than 2.5 cm from the bottom of the beaker. A standard motor driven device is used to move the basket assembly containing the capsules up and down through distance of 5 to 6 cm at a frequency of 28 to 32 cycles per minute. Perforated plastic discs may also be used in the test. These are placed on the top of capsules and impart an abrasive action to the capsules. The discs may or may not be meaningful or impart more sensitivity to the test, but they are useful for capsules that float. Operate the apparatus for the specified time. The capsule complies with the test, if the capsules disintegrate, and all particles pass through the 10-mesh screen in the time specified. If any residue remains, it must have a soft mass with no palpably firm core [47]. The capsule complies with the test according to USP, if all of the capsules have disintegrated completely. If 1 or 2 capsules fail to disintegrate completely,

repeat the test on 12 additional capsules. The requirement is met if not less than 16 of the total of 18 capsules tested are disintegrated [48,49]. According to IP and BP the disintegration time of various capsules is given in Table 1.5 and Table 1.6 respectively.

Table1.5. Disintegration time of various capsules according to IP

Capsule	Disintegration time(min)
Hard capsule	30
Soft capsule	60
Enteric capsules	60

Table 1.6. Disintegration time of various capsules according to BP

Capsule	Disintegration time(min)
Hard capsule	30
Soft capsule	30
Gastro resistance capsule	60
Rectal capsules	30
Vaginal capsules	30

2.4.8 Stability Test

The capsule manufacturers routinely conduct accelerated physical stability tests on all new capsule products as an integral part of the product development program. The following tests have proved adequate for determining the effect of the capsule shell content on the gelatin shell. The tests are strictly relevant to the integrity of the gelatin shell and should not be confused as stability tests for the active ingredients in the capsule content. The results of such tests are used as a guide for the reformulation of the capsule content or the capsule shell, or for the selection of the proper retail package. The test conditions for such accelerated stability tests are shown in above, Table 8. The capsules at these stations are observed periodically for 2 weeks. Both gross and subtle effects of the storage conditions on the capsule shell are noted and recorded. The control capsule should not be affected except at the 80 percent RH (relative humidity) station, where the capsule would react as described under the effects of high humidity [50,51].

2.5 QC Tests for Liquid Dosage Form

2.5.1 pH Test

This test measures the pH of a liquid to ensure that it is within a specified range. This is important because the pH can affect the stability and effectiveness of the medication[52]

2.5.2 Specific Gravity Test

This test measures the specific gravity of a liquid, which is its density relative to water. This is important because the specific gravity can be used to identify the liquid and to ensure that it is within a specified range[53].

2.5.3 Refractive Index Test

This test measures the refractive index of a liquid, which is a measure of how much the liquid bends light. This is important because the refractive index can be used to identify the liquid and to ensure that it is within a specified range[54].

2.5.4 Viscosity Test

This test measures the viscosity of a liquid, which is its resistance to flow. This is important because the viscosity can affect the pourability and stability of the syrup[55].

2.5.5 Clarity and Color Test

This test is performed visually to assess the clarity and colour of the syrup. The syrup should be free of any suspended particles and should be within a specified color range [56].

2.5.6 Assay Test

This test measures the total amount of active ingredient in a sample of syrup. This is important to ensure that the product contains the correct amount of medication [57].

3. CONCLUSION AND RECOMMENDATION

To ensure the quality of pharmaceuticals regulatory bodies are continually developing their requirements toward pharmaceutical companies. In pharmaceutical industry the maximum quality of pharmaceuticals, depends on the tests performed during manufacturing and after manufacturing of the pharmaceuticals as per specifications of the respective pharmacopoeias and the regulatory requirements of the particular countries. From the present study it is clearly revealed though various pharmacopoeias suggest different types of IPQC tests for pharmaceutical tablets and capsules with different specifications and standards but the main function of the all pharmacopoeias is to assure the maximum quality of pharmaceuticals for human health. During product development, many analytical techniques can be brought to bear, providing a characterization of the product and guiding the pathway to an optimum formula. Solid oral dosage forms easy to manufacture and stable, they are the most common form of self-medication. Immediate controlled and extended release solid oral dosage forms are easy to manufacture, reproducibly and provide convenient delivery systems for self-administered medications. Therefore modern analytical techniques have a crucial role in the designing formulation, API characterization, invitro study, stability study, quality control of various pharmaceutical solid oral dosage forms for intended purpose.

REFERENCES

1. SMR Dewan; A Alam; SK Ahamed, *Int. Res. J. of Pharm.*, 2013, 4(1), 96.
2. J Woodcock, *Ameri. Pharmace. Rev.*, 2004, 7(60), 10-15.
3. JM Fortunak1; RD Souza; AA Kulkarni; CL King; T Ellison; LSM Miranda, *Antivi. Thera.*, 2014, 19(3), 4-6.
4. T Mehmood; MR Salaria; GM Herani; MA Qureshi, *Ind. J. of Manage. & Soci. Sci.*, 2009, 3(2), 21-30.
5. L Levi; G walker, *Canadi. Medi. Associ.*, 2010, 91(15), 96.
6. P Tangri; P Mangain; Shaffi; AML Verma; Lakshmayya, *Int. J. of Ind. Pharm. and Bio Sci.*, 2012, 1(1), 49-51.
7. B Mazumder; S Bhattacharya; A Yadav, *Int. J. of PharmTech Res.*, 2011, 3(1), 366.
8. CH Teja; V Balamuralidhara; S Vinay; RS Bhat; TMP Kumar, *Int. J. of Pharm. Tea. & Prac.*, 2011, 2(4), 65.
9. S Vinay; RS Bhat; V Balamuralidhara; TMP Kumar, *Int. J. of Pharm.Tea. & Prac.*, 2011, 2(4), 176-183.
10. MS Amran. *Introduction to Pharmacy*, 2nd Edition, Krishnochura Prokashoni, Dhaka, 2015, 20-50.
11. Rohit S Gupta, Ratnadeep R Deshmukh, Priyanka U Randive, Akshay V Kshirsagar, Jaypalsing N Kayte (2018) *Study of Pharmaceutical Solid dosage forms using Invasive and Non Invasive Techniques*.
12. Krylov SN, Dovichi NJ (2000) Capillary electrophoresis for the analysis of biopolymers. *Anal Chem* 72: 111R-128R.

13. Ren JC (2000) High-throughput single-strand conformation polymorphism analysis by capillary electrophoresis. *J. Chromatogr. B* 741: 115-128.
14. Oda RP, Landers JP (1997) Introduction to capillary electrophoresis. In *Handbook of Capillary Electrophoresis*. In: Landers (Eds.), (2nd edn), CRC Press, NewYork, USA, p. 1-47.
15. Qiu, Y.; Chen, Y.; Zhang, G.G.; Yu, L.; Mantri, R.V. *Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice*; Academic press: Cambridge, MA, USA, 2016.
16. Mahato, R.I.; Narang, A.S. *Pharmaceutical dosage forms and drug delivery: Revised and expanded*; CRC press: Boca Raton, FL, USA, 2017
17. Jose Manuel Amigo (2010) Practical issues of hyperspectral imaging analysis of solid dosage forms, *Anal Bional Chem* pp. 93-109-114.
18. Salvador Garrigues (2013) Miguel de la Guardia, "Non-invasive analysis of solid samples", *Trends in Analytical Chemistry* 43: 161-173.
19. Rubio-Bonilla, M.V.; Londono, R.; Rubio, A. Liquid dosage forms. In *Pharmaceutical Manufacturing Handbook: Production and Processes*; John Wiley & Sons: Hoboken, NJ, USA, 2008; 5, 313–344.
20. LV Allen, NG Popovich, HC Ansel. *Ansel's pharmaceutical dosage forms and drug delivery systems*. 9th ed. New York: Lippincott Williams & Wilkins; 2011.
21. United States Pharmacopeia (USP). (2023). USP general chapter Assay. Rockville, MD: USP
22. Fuhrman, L., Jr. (2006). *Ansel's pharmaceutical dosage forms and drug delivery systems*, 8th edition. *American Journal of Pharmaceutical Education*, 70(3), 71.
23. Loyd V. Allen, Jr. Howard C. Ansel. *Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems*. Allen, Loyd V., Jr. Tablet. Philadelphia. 2001. 263-298
24. Kevin M. G. Taylor, Michael E. Aulton . *Aulton 's Pharmaceutics*. Göran Alderborn. Tablets and compaction .1988. 504-550
25. Leon Lachman, Herbert A. Lieberman, Joseph L. Kanig. *The Theory and Practice of Industrial Pharmacy*. GILBERT S. BANKER and NEIL R. ANDERSON . Tablet . Philadelphia . 1986 . 293_345
26. McKay, Gerard A.; Walters, Matthew R. (2013). "Non-Opioid Analgesics". *Lecture Notes Clinical Pharmacology and Therapeutics* (9th ed.). Hoboken: Wiley.
27. The United States Pharmacopeia 32–National Formulary 27. Rockville, MD: U.S. Pharmacopeial Convention, 2009.
28. World Health Organization (WHO). (2011). *Good practices for quality control laboratories* (2nd ed.). Geneva, Switzerland: WHO.
29. Aulton, M. E. (2017). *Pharmaceutics: The science of dosage form design* (5th ed.). London, UK: Pharmaceutical Press.
30. Unites States Pharmacopoeia Convention. *United States Pharmacopoeia 38-National Formulary 33*, Stationery Office, USA, 2010.
31. Enders, J., *Quality assurance and control*. In G. AR, *The Science and Practice of Pharmacy*, 2000; 980-985. New York: Lippincott Williams & Wilkins.
32. Mazumder, B., *Total Quality Management in Pharmaceuticals: A Review*. *International Journal of PharmTech Research*, 2011; 365-375.
33. N Mathur; R Kumar; K Tiwari; S Singh; N Fatima, *Worl. J. of Pharm. and Pharmace. Sci.*, 2015, 4(7), 979.

34. United States Pharmacopoeia Convention. United States Pharmacopoeia 38-National Formulary 33, Stationery Office, USA, 2010
35. British Pharmacopoeia Commission. British Pharmacopoeia, 13th Edition, Stationery Office, Great Britain, 2013.
36. The United States Pharmacopoeia 32–National Formulary 27. Rockville, MD: U.S. Pharmacopoeial Convention, 2009.
37. European Pharmacopoeia Commission. European Pharmacopoeia, 8th Edition, Council of Europe, Europe, 2013.
38. Society of Japanese Pharmacopoeia. Japanese Pharmacopoeia, 16th Edition, Pharmaceuticals and Medical Devices Agency, Japan, 2011.
39. World Health Organization (WHO). International Pharmacopoeia, 5th Edition, WHO, Switzerland, 2015.
40. E Jatto, AO Okhamafe. An overview of pharmaceutical validation and process controls in drug development. *Trop J Pharm Res.* 2002;1(2):116-117.
41. LV Allen, NG Popovich, HC Ansel. *Ansel's pharmaceutical dosage forms and drug delivery systems.* 9th ed. New York: Lippincott Williams & Wilkins; 2011.
42. E Jatto, AO Okhamafe. An overview of pharmaceutical validation and process controls in drug development. *Trop J Pharm Res.* 2002;1(2):116-117.
43. LV Allen, NG Popovich, HC Ansel. *Ansel's pharmaceutical dosage forms and drug delivery systems.* 9th ed. New York: Lippincott Williams & Wilkins; 2011.
44. LV Allen, NG Popovich, HC Ansel. *Ansel's pharmaceutical dosage forms and drug delivery systems.* 9th ed. New York: Lippincott Williams & Wilkins; 2017.
45. Gonzalez, S., D. Miller, and S.P. Murphy, Maintenance of sterility in 1-mL polypropylene syringes. *American journal of health-system pharmacy*, 2007. 64(18): p. 1962-1964.
46. Van Schoor, J., Using gargles and mouthwashes: Medicine cupboard. *SA Pharmacist's Assistant*, 2011. 11(2): p. 26.
47. Patel, H.; Shah, V.; Upadhyay, U. New pharmaceutical excipients in solid dosage forms-A review. *Int. J. Pharm. Life Sci.* 2011, 2, 1006–1019.
48. Halasz, H.; Antal, I. Drug excipients. *Curr. Med. Chem.* 2006, 13, 2535–2563.
49. Tanaka, K., et al., Comparative Study of General Notices in Pharmacopoeias in Japan, the United States, and Europe. *Chemical and Pharmaceutical Bulletin*, 2023. 71(1): p. 41-51.[2]
50. Block, L., H. Wang, and C. Sheehan, Characterization of Polymeric Excipients. *Pharmaceutical Technology*, 2017. 2017(2).
51. Tanaka, K., et al., Comparative Study of General Notices in Pharmacopoeias in Japan, the United States, and Europe. *Chemical and Pharmaceutical Bulletin*, 2023. 71(1): p. 50-55.
52. Nelson, S., et al., Calculating the refractive index for pediatric parenteral nutrient solutions. *American journal of health-system pharmacy*, 2013. 70(4): p. 350-355.
53. Boyte, M.-E., et al., A Review of Probiotic Ingredient Safety Supporting Monograph Development Conducted by the United States Pharmacopoeia (USP). *Journal of Dietary Supplements*, 2024: p. 1-39.
54. Al Ali, L., et al., Pharmaceutical equivalency of locally and regionally manufactured generic pharmaceutical products in UAE[3]. *Saudi Pharmaceutical Journal*, 2022. 30(9): p. 1243-1251

55. Davies, D.R. and S. Chacko, Antibody structure. Accounts of chemical research, 1993. 26(8): p. 421-427.
56. Gonzalez, S., D. Miller, and S.P. Murphy, Maintenance of sterility in 1-mL polypropylene syringes. American journal of health-system pharmacy, 2007. 64(18): p. 1962-1964
57. Clark, M.R., Antibody Engineering. Chem. Immunol, 1997. 65: p. 88-110